HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Testosterone (Sustanon)

A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.
Also Known As:
Sustanon; AndroGel; Androderm; Testim; Testoderm; 17-beta-Hydroxy-4-Androsten-3-one; 17-beta-Hydroxy-8 alpha-4-Androsten-3-one; 8-Isotestosterone; Andropatch; Androtop; Histerone; Sterotate; Testolin; Testopel; Testosterone Sulfate; 17 beta Hydroxy 4 Androsten 3 one; 17 beta Hydroxy 8 alpha 4 Androsten 3 one; 8 Isotestosterone; Androst-4-en-17beta-ol-3-one
Networked: 20642 relevant articles (983 outcomes, 2920 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Maggi, Mario: 94 articles (10/2022 - 05/2004)
2. Bhasin, Shalender: 91 articles (10/2022 - 07/2002)
3. Morgentaler, Abraham: 77 articles (01/2022 - 12/2003)
4. Saad, Farid: 67 articles (02/2022 - 01/2006)
5. Corona, Giovanni: 63 articles (12/2021 - 05/2006)
6. Ramasamy, Ranjith: 60 articles (11/2022 - 12/2006)
7. Khera, Mohit: 55 articles (11/2022 - 11/2007)
8. Handelsman, David J: 53 articles (10/2022 - 01/2003)
9. Grossmann, Mathis: 53 articles (07/2022 - 05/2008)
10. Basaria, Shehzad: 53 articles (01/2022 - 01/2003)

Related Diseases

1. Hypogonadism (Hypergonadotropic Hypogonadism)
2. Insulin Resistance
3. Prostatic Neoplasms (Prostate Cancer)
4. Body Weight (Weight, Body)
05/23/2013 - "In an initial dose-response study, SIL in a dose of 50mg/kg was the most effective in preventing the rise in prostate weight, prostate weight/body weight ratio and histopathologic changes induced by testosterone. "
05/01/2015 - "PFE at a dose of 100 mg/kg was the most effective in decreasing testosterone-induced increase in prostate weight, prostate weight/body weight ratio, and PAP levels by 30.8%, 55%, and 68% respectively and in preventing the accompanying histological changes. "
10/17/2019 - "VISPO exhibited superior efficacy compared to SPO as evident from the significant decrease in prostate weight to body weight ratio, serum testosterone level and increase in growth inhibition of prostate tissue compared to BPH group (p < 0.001). "
01/01/2018 - "Substitution of VPA with LTG results in significant reduction in mean testosterone levels (p=0.005) and means body weight at 6th month (p=0.01). "
01/01/2015 - "The body weight was decreased significantly in CIS 10 mg/kg, CIS 10 mg/kg + MOTILIPERM 100 mg/kg/day, CIS 10 mg/kg + MOTILIPERM 200 mg/kg/day compared with CTR (p < 0.001) however, it was increased in CIS 10 mg/kg + MOTILIPERM 100 mg/kg/day, CIS 10 mg/kg + MOTILIPERM 200 mg/kg/day compared with CIS 10 mg/kg. The decreased weight of epididymis and prostate were increased significantly in CIS 10 mg/kg + MOTILIPERM 100 mg/kg/day compared with CIS 10 mg/kg. Sperm count, sperm motility, sperm apoptosis, MDA of testis tissue, spermatogenic cell density, Johnsen's score, and total testosterone were also significantly improved by MOTILIPERM treatment. "
5. Erectile Dysfunction

Related Drugs and Biologics

1. Androgens
2. Estradiol (Delestrogen)
3. Insulin (Novolin)
4. Hormones (Hormone)
5. Metformin (Glucophage)
6. Luteinizing Hormone (Lutropin)
7. Estrogens (Estrogen)
8. Lipids
9. Glucose (Dextrose)
10. Gonadotropin-Releasing Hormone (GnRH)

Related Therapies and Procedures

1. Therapeutics
2. Castration
3. Injections
4. Orchiectomy (Orchidectomy)
5. Drug Therapy (Chemotherapy)